R&D News | pharmaphorum

News

Tidmarsh to stand in for Prasad's role at CBER

Following Vinay Prasad's abrupt departure as CBER director, FDA has asked CDER head George Tidmarsh to take on both roles while a successor is sought.

News

GSK suffers a setback with its TIM-3 programme

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3.

News

White House retreats from block on NIH research funding

A move by the Trump administration to block NIH research funding for external research teams appears to have been abandoned.

News

Vinay Prasad abruptly departs from the FDA

The disruption at the FDA continues with the departure of CBER director Vinay Prasad, less than three months after taking on the role.

News

Pharma tariffs set to arrive with US-EU trade deal

After some initial confusion, it has been confirmed that the 15% tariff rate on US imports from the EU will extend to pharmaceuticals.

News

Celcuity eyes big market opportunity after breast cancer win

Celcuity shares rocket on a big win for its lead drug gedatolisib in advanced breast cancer, catapulting its value to almost $1.4 billion.

Tidmarsh to stand in for Prasad's role at CBER

GSK suffers a setback with its TIM-3 programme

White House retreats from block on NIH research funding

Vinay Prasad abruptly departs from the FDA

Pharma tariffs set to arrive with US-EU trade deal

Celcuity eyes big market opportunity after breast cancer win

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks